Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial

被引：6

作者：

Hu, Huabin ^{[1
,2
,3
]}

Zhang, Jianwei ^{[1
,2
,3
]}

Li, Yunfeng ^{[4
]}

Wang, Xiaozhong ^{[5
]}

Wang, Ziqiang ^{[6
]}

Wang, Hui ^{[2
,3
,7
]}

Kang, Liang ^{[2
,3
,7
]}

Liu, Ping ^{[4
]}

Lan, Ping ^{[2
,3
,7
]}

Wu, Xiaojian ^{[2
,3
,7
]}

Zhen, Yunhuan ^{[8
]}

Pei, Haiping ^{[9
]}

Huang, Zhongcheng ^{[10
]}

Zhang, Hao ^{[11
]}

Chen, Wenbin ^{[12
]}

Zeng, Yongming ^{[13
]}

Lai, Jiajun ^{[14
]}

Wei, Hongbo ^{[15
]}

Huang, Xuefeng ^{[16
]}

Chen, Jiansi ^{[17
]}

Chen, Jigui ^{[18
]}

Tao, Kaixiong ^{[19
]}

Xu, Qingwen ^{[20
]}

Peng, Xiang ^{[21
]}

Liang, Junlin ^{[22
]}

Cai, Guanfu ^{[23
]}

Ding, Kefeng ^{[24
]}

Ding, Zhijie ^{[25
]}

Hu, Ming ^{[26
]}

Zhang, Wei ^{[27
]}

Tang, Bo ^{[28
]}

Hong, Chuyuan ^{[29
]}

Cao, Jie ^{[30
]}

Huang, Zonghai ^{[31
]}

Cao, Wuteng ^{[32
]}

Li, Fangqian ^{[32
]}

Wang, Xinhua ^{[32
]}

Wang, Chao ^{[33
]}

Huang, Yan ^{[33
]}

Zhao, Yandong ^{[33
]}

Cai, Yue ^{[1
,2
,3
]}

Ling, Jiayu ^{[1
,2
,3
]}

Xie, Xiaoyu ^{[1
,2
,3
]}

Wu, Zehua ^{[1
,2
,3
]}

Shi, Lishuo ^{[34
]}

Ling, Li ^{[35
,36
]}

Liu, Hao ^{[37
]}

Wang, Jianping ^{[2
,3
,7
]}

Huang, Meijin ^{[2
,3
,7
]}

Deng, Yanhong ^{[1
,2
,3
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China

[2] Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, Guangzhou, Peoples R China

[3] Sun Yat Sen Univ, Affiliated Hosp 6, Biomed Innovat Ctr, Guangzhou, Peoples R China

[4] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Dept Colorectal Surg, Kunming, Peoples R China

[5] Shantou Cent Hosp, Dept Gastrointestinal Surg, Shantou, Peoples R China

[6] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg,Sch Med, Chengdu, Peoples R China

[7] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Gen Surg, Guangzhou, Peoples R China

[8] Guizhou Med Univ, Affiliated Hosp, Dept Colorectal Surg, Guiyang, Peoples R China

[9] Cent South Univ, Xiangya Hosp, Dept Gen Surg, Changsha, Peoples R China

[10] Hunan Prov Peoples Hosp, Dept Gen Surg, Changsha, Peoples R China

[11] Dongguan Kanghua Hosp, Dept Gen Surg, Dongguan, Peoples R China

[12] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Colorectal Surg, Hangzhou, Peoples R China

[13] Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Gastrointestinal Surg, Shantou, Peoples R China

[14] Yuebei Peoples Hosp, Dept Gastrointestinal Surg, Shaoguan, Peoples R China

[15] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gastrointestinal Surg, Guangzhou, Peoples R China

[16] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Schoolof Med, Hangzhou, Peoples R China

[17] Guangxi Med Univ, Canc Hosp, Dept Gastrointestinal Surg, Nanning, Peoples R China

[18] Eighth Hosp Wuhan, Dept Surg, Wuhan, Peoples R China

[19] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China

[20] Guangdong Med Univ, Affiliated Hosp, Dept Gastrointestinal Surg, Zhanjiang, Peoples R China

[21] First Peoples Hosp Foshan, Dept Gastrointestinal Surg, Foshan, Peoples R China

[22] Guangxi Med Univ, Affiliated Hosp 1, Dept Coloproctol Surg, Nanning, Peoples R China

[23] Guangdong Prov Peoples Hosp, Dept Gastrointestinal Surg, Guangzhou, Peoples R China

[24] Zhejiang Univ, Affiliated Hosp 2, Canc Ctr, Peoples Dept Colorectal Surg & Oncol,Sch Med, Hangzhou, Peoples R China

[25] Xiamen Univ, Zhongshan Hosp, Dept Gastrointestinal Surg, Xiamen, Peoples R China

[26] Guangzhou Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Guangzhou, Peoples R China

[27] Naval Med Univ, Affiliated Hosp 1, Dept Colorectal Surg, Shanghai, Peoples R China

[28] Army Med Univ, Hosp Affiliated 1, Dept Gen Surg, Chongqing, Peoples R China

[29] Guangzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Guangzhou, Peoples R China

[30] Guangzhou First Peoples Hosp, Dept Gen Surg, Guangzhou, Peoples R China

[31] Southern Med Univ, Zhujiang Hosp, Dept Gen Surg, Guangzhou, Peoples R China

[32] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiol, Guangzhou, Peoples R China

[33] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pathol, Guangzhou, Peoples R China

[34] Sun Yat Sen Univ, Affiliated Hosp 6, Clin Res Ctr, Guangzhou, Peoples R China

[35] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat, Guangzhou, Peoples R China

[36] Sun Yat Sen Univ, Ctr Migrant Hlth Policy, Guangzhou, Peoples R China

[37] Rutgers Canc Inst New Jersey, Rutgers Sch Publ Hlth, Dept Biostat & Epidemiol, Biostat Shared Resource, Brunswick, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 25期

关键词：

ADJUVANT TREATMENT; COMPUTED-TOMOGRAPHY; PREOPERATIVE CHEMOTHERAPY; OPEN-LABEL; FLUOROURACIL; LEUCOVORIN; BEVACIZUMAB; IRINOTECAN; CARCINOMA; CETUXIMAB;

D O I：

10.1200/JCO.23.01889

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEThe role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear. This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or capecitabine and oxaliplatin (CAPOX) as NAC could improve outcomes in patients with locally advanced colon cancer versus upfront surgery.PATIENTS AND METHODSOPTICAL was a randomized, phase III trial in patients with clinically staged locally advanced colon cancer (T3 with extramural spread into the mesocolic fat >= 5 mm or T4). Patients were randomly assigned 1:1 to receive six preoperative cycles of mFOLFOX6 or four cycles of CAPOX, followed by surgery and adjuvant chemotherapy (NAC group), or immediate surgery and the physician's choice of adjuvant chemotherapy (upfront surgery group). The primary end point was 3-year disease-free survival (DFS) assessed in the modified intention-to-treat (mITT) population.RESULTSBetween January 2016 and April 2021, of the 752 patients enrolled, 744 patients were included in the mITT analysis (371 in the NAC group; 373 in the upfront surgery group). At a median follow-up of 48.0 months (IQR, 46.0-50.1), 3-year DFS rates were 82.1% in the NAC group and 77.5% in the upfront surgery group (stratified hazard ratio [HR], 0.74 [95% CI, 0.54 to 1.03]). The R0 resection was achieved in 98% of patients who underwent surgery in both groups. Compared with upfront surgery, NAC resulted in a 7% pathologic complete response rate (pCR), significantly lower rates of advanced tumor staging (pT3-4: 77% v 94%), lymph node metastasis (pN1-2: 31% v 46%), and potentially improved overall survival (stratified HR, 0.44 [95% CI, 0.25 to 0.77]).CONCLUSIONNAC with mFOLFOX6 or CAPOX did not show a significant DFS benefit. However, this neoadjuvant approach was safe, resulted in substantial pathologic downstaging, and appears to be a viable therapeutic option for locally advanced colon cancer.

引用

页码：2978 / 2988

页数：29

共 45 条

[1] Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial
Alberts, Steven R.
Sargent, Daniel J.
Nair, Suresh
Mahoney, Michelle R.
Mooney, Margaret
Thibodeau, Stephen N.
Smyrk, Thomas C.
Sinicrope, Frank A.
Chan, Emily
Gill, Sharlene
Kahlenberg, Morton S.
Shields, Anthony F.
Quesenberry, James T.
Webb, Thomas A.
Farr, Gist H., Jr.
Pockaj, Barbara A.
Grothey, Axel
Goldberg, Richard M.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13): : 1383 - 1393
[2] Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
Allegra, Carmen J.
Yothers, Greg
O'Connell, Michael J.
Sharif, Saima
Petrelli, Nicholas J.
Colangelo, Linda H.
Atkins, James N.
Seay, Thomas E.
Fehrenbacher, Louis
Goldberg, Richard M.
O'Reilly, Seamus
Chu, Luis
Azar, Catherine A.
Lopa, Samia
Wolmark, Norman
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) : 11 - 16
[3] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
Andre, T
Boni, C
Mounedji-Boudiaf, L
Navarro, M
Tabernero, J
Hickish, T
Topham, C
Zaninelli, M
Clingan, P
Bridgewater, J
Tabah-Fisch, I
de Gramont, A
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
[4] Bancewicz J, 2002, LANCET, V359, P1727
[5] Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
Cercek, Andrea
Fernandes, Gustavo Dos Santos
Roxburgh, Campbell S.
Ganesh, Karuna
Ng, Shu
Sanchez-Vega, Francisco
Yaeger, Rona
Segal, Neil H.
Reidy-Lagunes, Diane L.
Varghese, Anna M.
Markowitz, Arnold
Wu, Chao
Szeglin, Bryan
Sauve, Charles-Etienne Gabriel
Salo-Mullen, Erin
Tran, Christina
Patel, Zalak
Krishnan, Asha
Tkachuk, Kaitlyn
Nash, Garrett M.
Guillem, Jose
Paty, Philip B.
Shia, Jinru
Schultz, Nikolaus
Garcia-Aguilar, Julio
Diaz, Luis A.
Goodman, Karyn
Saltz, Leonard B.
Weiser, Martin R.
Smith, J. Joshua
Stadler, Zsofia K.
[J]. CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3271 - 3279
[6] Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Chalabi, Myriam
Fanchi, Lorenzo F.
Dijkstra, Krijn K.
Van den Berg, Jose G.
Aalbers, Arend G.
Sikorska, Karolina
Lopez-Yurda, Marta
Grootscholten, Cecile
Beets, Geerard L.
Snaebjornsson, Petur
Maas, Monique
Mertz, Marjolijn
Veninga, Vivien
Bounova, Gergana
Broeks, Annegien
Beets-Tan, Regina G.
de Wijkerslooth, Thomas R.
van Lent, Anja U.
Marsman, Hendrik A.
Nuijten, Elvira
Kok, Niels F.
Kuiper, Maria
Verbeek, Wieke H.
Kok, Marleen
Van Leerdam, Monique E.
Schumacher, Ton N.
Voest, Emile E.
Haanen, John B.
[J]. NATURE MEDICINE, 2020, 26 (04) : 566 - +
[7] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
Cunningham, David
Allum, William H.
Stenning, Sally P.
Thompson, Jeremy N.
Van de Velde, Cornelis J. H.
Nicolson, Marianne
Scarffe, J. Howard
Lofts, Fiona J.
Falk, Stephen J.
Iveson, Timothy J.
Smith, David B.
Langley, Ruth E.
Verma, Monica
Weeden, Simon
Chua, Yu Jo
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) : 11 - 20
[8] Evaluating the oncological safety of neoadjuvant chemotherapy in locally advanced colon carcinoma: a systematic review and meta-analysis of randomised clinical trials and propensity-matched studies
Davey, Matthew G.
Amir, Amira H.
Ryan, Odhran K.
Donnelly, Mark
Donlon, Noel E.
Regan, Mark
Meshkat, Babak
Nugent, Emmeline
Joyce, Myles
Hogan, Aisling M.
[J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2023, 38 (01)
[9] Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
de Gramont, Aimery
Van Cutsem, Eric
Schmoll, Hans-Joachim
Tabernero, Josep
Clarke, Stephen
Moore, Malcolm J.
Cunningham, David
Cartwright, Thomas H.
Hecht, J. Randolph
Rivera, Fernando
Im, Seock-Ah
Bodoky, Gyoergy
Salazar, Ramon
Maindrault-Goebel, Frederique
Shacham-Shmueli, Einat
Bajetta, Emilio
Makrutzki, Martina
Shang, Aijing
Andre, Thierry
Hoff, Paulo M.
[J]. LANCET ONCOLOGY, 2012, 13 (12) : 1225 - 1233
[10] Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial
Deng, Yanhong
Chi, Pan
Lan, Ping
Wang, Lei
Chen, Weiqing
Cui, Long
Chen, Daoda
Cao, Jie
Wei, Hongbo
Peng, Xiang
Huang, Zonghai
Cai, Guanfu
Zhao, Ren
Huang, Zhongcheng
Xu, Lin
Zhou, Hongfeng
Wei, Yisheng
Zhang, Hao
Zheng, Jian
Huang, Yan
Zhou, Zhiyang
Cai, Yue
Kang, Liang
Huang, Meijin
Peng, Junsheng
Ren, Donglin
Wang, Jianping
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) : 3300 - +

← 1 2 3 4 5 →